Levetiracetam (Keppra) for Post-Traumatic Seizures After a TBI: PI Patient Guide

James Wong — Founder & Pharmacist, LienScripts | February 12, 2026 | 7 min read

Levetiracetam (Keppra) is the preferred antiepileptic medication for both acute seizure prophylaxis and long-term treatment of post-traumatic epilepsy after traumatic brain injury. Its presence in a PI pharmacy record is powerful documentation of a significant TBI — and pharmacy liens cover it at no upfront cost for uninsured patients.

Seizures After a Traumatic Brain Injury: What You Need to Know

Traumatic brain injury (TBI) is one of the strongest risk factors for developing epilepsy in adults. When the brain sustains mechanical trauma — bruising, tearing, hemorrhage, shearing of axonal fibers — the disruption to normal neuronal networks can initiate epileptogenic processes that produce seizures acutely, days later, or months to years after the injury.

Levetiracetam, sold under the brand name Keppra, has become the antiepileptic medication of choice for TBI patients in the United States. Understanding why levetiracetam is preferred over older agents, how it is used in both the acute prophylactic and chronic treatment settings, and how a pharmacy lien covers it for uninsured PI patients provides critical context for patients and attorneys working through cases involving significant head trauma.

[!KEY] A levetiracetam prescription in a PI patient's pharmacy record is one of the strongest pharmacological indicators of TBI severity. Neurologists do not prescribe antiepileptic prophylaxis after a minor bump to the head — they prescribe it for TBIs with documented hemorrhage, contusion, depressed skull fracture, or penetrating injury. A Keppra prescription anchors the TBI narrative with objective, physician-confirmed severity documentation.

Understanding Post-Traumatic Seizures and Epilepsy

Clinicians categorize post-traumatic seizures by timing:

Immediate Seizures (Within 24 Hours)

Seizures occurring within the first 24 hours of injury are called immediate post-traumatic seizures. They are driven by the acute metabolic disruption of the injury — electrolyte shifts, excitotoxicity from massive glutamate release, and direct cortical depolarization. They are not predictive of long-term epilepsy but require immediate management.

Early Post-Traumatic Seizures (Days 1–7)

Seizures occurring between day 1 and day 7 post-injury are classified as early post-traumatic seizures. These are the primary target of pharmacological prophylaxis — antiepileptic medications given specifically to prevent this seizure window. They carry a higher risk of secondary brain injury (increased intracranial pressure, hypoxia, metabolic stress) and are associated with worse outcomes.

Late Post-Traumatic Seizures (After Day 7)

Seizures occurring more than seven days after injury, and particularly those occurring after hospital discharge, indicate that the brain has undergone epileptogenesis — a process by which the injury has permanently altered neuronal networks to generate spontaneous, recurrent seizure activity. When these seizures recur, the clinical diagnosis is post-traumatic epilepsy (PTE).

PTE affects an estimated 2–50% of TBI patients, depending on injury severity. Moderate-to-severe TBI, penetrating head injury, intracranial hemorrhage, and depressed skull fracture carry the highest risk.

[!SOURCE] The incidence of post-traumatic epilepsy and risk factors by injury type are reviewed in this landmark study: https://pubmed.ncbi.nlm.nih.gov/9040852/

Mechanism of Action: SV2A Modulation

Levetiracetam has a unique mechanism of action that distinguishes it from every other antiepileptic medication. It binds to synaptic vesicle protein 2A (SV2A), a transmembrane protein found on synaptic vesicles in neurons throughout the central nervous system.

SV2A is involved in regulating synaptic vesicle exocytosis — the process by which neurons release neurotransmitters into the synaptic cleft. By binding SV2A, levetiracetam modulates vesicle release in a way that reduces abnormal, synchronized neuronal firing (the electrophysiological signature of a seizure) without broadly suppressing normal neuronal activity.

This is a critical distinction from older antiepileptic drugs:

• Phenytoin (Dilantin) blocks sodium channels broadly — it prevents seizures but also suppresses normal neuronal transmission
• Valproate modulates multiple targets including sodium channels, GABA metabolism, and calcium channels — effective but carries significant drug interaction and teratogenicity risks
• Levetiracetam selectively modulates abnormal synchronous firing via SV2A without broadly impairing normal neuronal function

The SV2A mechanism explains why levetiracetam is well-tolerated in patients who cannot afford cognitive side effects — a critical consideration for TBI patients whose baseline cognition is already impaired by the injury itself.

Why Levetiracetam Is Preferred Over Phenytoin in TBI

For decades, phenytoin (Dilantin) was the standard of care for post-traumatic seizure prophylaxis. Levetiracetam has substantially displaced phenytoin in TBI practice for several reasons that matter clinically — and that attorneys should understand when reviewing the treatment record:

1. No Cognitive Blunting

Phenytoin impairs cognitive function, attention, and processing speed — effects that compound the cognitive deficits already produced by TBI. For a patient trying to participate in physical rehabilitation, follow treatment instructions, and prepare for litigation, additional drug-induced cognitive impairment is both medically and legally harmful.

Levetiracetam does not produce phenytoin-type cognitive blunting. It is associated with mood and behavioral side effects (discussed below), but its cognitive profile is substantially cleaner than phenytoin.

2. Simpler Therapeutic Drug Monitoring

Phenytoin has a narrow therapeutic window and nonlinear pharmacokinetics — small dose changes can produce disproportionate changes in blood levels, requiring frequent blood tests and dose adjustments. Levetiracetam has linear pharmacokinetics: predictable blood levels, no required therapeutic drug monitoring in most patients, and simple twice-daily dosing.

3. Fewer Drug Interactions

Phenytoin is a potent CYP450 inducer — it accelerates the metabolism of dozens of other medications including corticosteroids, anticoagulants, and antibiotics that TBI patients commonly require. This creates complex drug interaction management challenges in the acute hospital and post-discharge periods.

Levetiracetam does not significantly induce or inhibit CYP450 enzymes. It is not protein-bound. Its interaction profile is minimal, making it far easier to manage in patients on multiple medications.

4. No Cardiovascular Side Effects

Phenytoin requires slow intravenous infusion due to cardiac toxicity risk; rapid infusion can cause hypotension and arrhythmia. Levetiracetam can be infused more rapidly without cardiovascular risk — a practical advantage in the acute TBI setting.

[!KEY] When a neurologist chooses levetiracetam over phenytoin for a TBI patient, they are making an evidence-based decision that reflects the clinical complexity of the case. The prescription itself signals that the treating physician considers the TBI significant enough to warrant antiepileptic therapy and has selected the modern standard of care.

Clinical Use Patterns in TBI

Acute Prophylaxis: The 7-Day Course

Clinical guidelines from the Brain Trauma Foundation recommend 7 days of antiepileptic prophylaxis following severe TBI (GCS ≤ 8), moderate TBI with identified risk factors (intracranial hemorrhage, contusion, depressed skull fracture), or penetrating head injury. Levetiracetam is the most commonly used agent for this purpose.

The 7-day course is intended to prevent early post-traumatic seizures during the highest-risk window. After day 7, prophylaxis is typically discontinued unless the patient has experienced early post-traumatic seizures, because extended prophylaxis has not been shown to prevent late PTE.

A pharmacy record showing a 7-day levetiracetam course dispensed shortly after an accident documents an acute serious TBI — neurologists do not initiate this protocol for concussions or minor head trauma.

Long-Term Treatment for Post-Traumatic Epilepsy

When a patient develops late post-traumatic seizures (after day 7), long-term antiepileptic therapy is initiated. Levetiracetam is a first-line option. Dosing typically starts at 500 mg twice daily and is titrated based on response and tolerability, with a therapeutic range generally between 1,000 mg and 3,000 mg per day in two divided doses.

Treatment duration for PTE is individualized — some patients achieve seizure freedom and eventually taper off medication; others require long-term or lifetime antiepileptic therapy. For PI cases, ongoing levetiracetam use through the litigation period creates a continuous pharmacy record documenting that the seizure disorder persists as a long-term consequence of the injury.

Side Effects and Clinical Considerations

Levetiracetam is generally well-tolerated. The most clinically significant side effects in the PI population are:

• Irritability and mood changes: The most frequently reported behavioral effect is increased irritability, sometimes called "Keppra rage" colloquially in the patient community. This is a recognized side effect, typically dose-dependent, and managed through dose adjustment or supplemental vitamin B6 in some cases.
• Drowsiness and fatigue: More common early in therapy and with higher doses
• Dizziness and coordination problems: Usually transient
• Headache: Noted in clinical trials

Levetiracetam is renally cleared, so dose adjustment is required in patients with significant renal impairment. It is not hepatically metabolized and does not interact with most other medications.

Pharmacy Lien Coverage for Levetiracetam

Levetiracetam is available as a generic medication and is covered under pharmacy lien arrangements. PI patients who are uninsured, underinsured, or who do not want their seizure diagnosis routed through health insurance can receive levetiracetam through a pharmacy lien at no upfront cost.

For patients on long-term PTE treatment — who may be taking levetiracetam for the entire duration of a PI case spanning 12–36 months — pharmacy liens provide financial access to the medication that would otherwise be interrupted if the patient cannot afford out-of-pocket costs.

The pharmacy lien record for levetiracetam also functions as a medical documentation tool. Each monthly fill, with its fill date and prescribing physician, creates a dated timeline of ongoing seizure management that becomes part of the demand package. For cases involving TBI with post-traumatic epilepsy, this record substantiates permanent or long-term neurological injury in a concrete, verifiable way.

Documentation Impact for TBI Claims

From an attorney's standpoint, levetiracetam in the pharmacy record has specific evidentiary weight that goes beyond most other medications:

1. TBI severity indicator: Antiepileptic prescriptions are not written for mild concussions. Their presence indicates a TBI that the treating neurologist considered serious enough to warrant seizure prevention or treatment.

2. Neurologist involvement documented: Levetiracetam is typically prescribed by a neurologist or neurosurgeon — a specialist whose involvement documents that the TBI required specialist-level care.

3. Causal chain to accident: The prescription initiation date, when correlated to the accident date, establishes a direct temporal link between the trauma and the seizure disorder — the foundational element of medical causation.

4. Long-term consequence documentation: Ongoing PTE treatment extending months or years into the case documents that the TBI produced a permanent or long-duration neurological condition — the type of injury that supports significant non-economic and future medical damages.

Related Resources

• Concussion and TBI Medication Guide
• Meclizine for Vertigo After a TBI or Whiplash
• Pharmacy Lien Support for Neurology Patients
• Gabapentin vs. Pregabalin for Neuropathic Pain
• What Is a Pharmacy Lien?